Acceptability of chemoprevention trials in high-risk subjects

Research output: Contribution to journalArticle

Abstract

The development and current widespread acceptance of clinical trials is one of the major conceptual advances in research medicine introduced during the second half of the 20th century. Despite general agreement on the scientific merits of randomization, many patients and physicians are however reluctant to participate in randomized, controlled trials. If we focus on chemoprevention in healthy subjects, it is even more essential to evaluate the ethics, logistics, patient's and doctor's acceptability, acute and late toxic effect, patient accrual and compliance of treatment. Furthermore, the decision-making process about participating in a cancer chemoprevention trial is often poorly understood. Adherence to a cancer prevention trial requires in fact a strong sense of awareness and an ability to carefully assess risks and benefits. We review the main aspects in the chemo-preventive approach to patients at high risk for breast and ovarian cancer, focusing on different pharmacological risk reduction strategies, ongoing phase III chemoprevention studies in carriers of BRCA1/2 germline mutation, the psychological and clinical factors implicated in decision making about a trial, and the possible impact of the trial design on the overall acceptability and adherence.

Original languageEnglish
Article numbermdt328
JournalAnnals of Oncology
Volume24
Issue numberSUPPL.B
DOIs
Publication statusPublished - 2013

Fingerprint

Chemoprevention
Decision Making
Aptitude
Germ-Line Mutation
Poisons
Risk Reduction Behavior
Patient Compliance
Random Allocation
Ethics
Ovarian Neoplasms
Neoplasms
Healthy Volunteers
Randomized Controlled Trials
Medicine
Clinical Trials
Pharmacology
Breast Neoplasms
Psychology
Physicians
Research

Keywords

  • BRCA mutations
  • Chemoprevention
  • Clinical trials
  • Ethics
  • Patient adherence

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Acceptability of chemoprevention trials in high-risk subjects. / Bonanni, B.; Lazzeroni, M.

In: Annals of Oncology, Vol. 24, No. SUPPL.B, mdt328, 2013.

Research output: Contribution to journalArticle

@article{90ad812ebf6d4356a3d2b95bc682a288,
title = "Acceptability of chemoprevention trials in high-risk subjects",
abstract = "The development and current widespread acceptance of clinical trials is one of the major conceptual advances in research medicine introduced during the second half of the 20th century. Despite general agreement on the scientific merits of randomization, many patients and physicians are however reluctant to participate in randomized, controlled trials. If we focus on chemoprevention in healthy subjects, it is even more essential to evaluate the ethics, logistics, patient's and doctor's acceptability, acute and late toxic effect, patient accrual and compliance of treatment. Furthermore, the decision-making process about participating in a cancer chemoprevention trial is often poorly understood. Adherence to a cancer prevention trial requires in fact a strong sense of awareness and an ability to carefully assess risks and benefits. We review the main aspects in the chemo-preventive approach to patients at high risk for breast and ovarian cancer, focusing on different pharmacological risk reduction strategies, ongoing phase III chemoprevention studies in carriers of BRCA1/2 germline mutation, the psychological and clinical factors implicated in decision making about a trial, and the possible impact of the trial design on the overall acceptability and adherence.",
keywords = "BRCA mutations, Chemoprevention, Clinical trials, Ethics, Patient adherence",
author = "B. Bonanni and M. Lazzeroni",
year = "2013",
doi = "10.1093/annonc/mdt328",
language = "English",
volume = "24",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "SUPPL.B",

}

TY - JOUR

T1 - Acceptability of chemoprevention trials in high-risk subjects

AU - Bonanni, B.

AU - Lazzeroni, M.

PY - 2013

Y1 - 2013

N2 - The development and current widespread acceptance of clinical trials is one of the major conceptual advances in research medicine introduced during the second half of the 20th century. Despite general agreement on the scientific merits of randomization, many patients and physicians are however reluctant to participate in randomized, controlled trials. If we focus on chemoprevention in healthy subjects, it is even more essential to evaluate the ethics, logistics, patient's and doctor's acceptability, acute and late toxic effect, patient accrual and compliance of treatment. Furthermore, the decision-making process about participating in a cancer chemoprevention trial is often poorly understood. Adherence to a cancer prevention trial requires in fact a strong sense of awareness and an ability to carefully assess risks and benefits. We review the main aspects in the chemo-preventive approach to patients at high risk for breast and ovarian cancer, focusing on different pharmacological risk reduction strategies, ongoing phase III chemoprevention studies in carriers of BRCA1/2 germline mutation, the psychological and clinical factors implicated in decision making about a trial, and the possible impact of the trial design on the overall acceptability and adherence.

AB - The development and current widespread acceptance of clinical trials is one of the major conceptual advances in research medicine introduced during the second half of the 20th century. Despite general agreement on the scientific merits of randomization, many patients and physicians are however reluctant to participate in randomized, controlled trials. If we focus on chemoprevention in healthy subjects, it is even more essential to evaluate the ethics, logistics, patient's and doctor's acceptability, acute and late toxic effect, patient accrual and compliance of treatment. Furthermore, the decision-making process about participating in a cancer chemoprevention trial is often poorly understood. Adherence to a cancer prevention trial requires in fact a strong sense of awareness and an ability to carefully assess risks and benefits. We review the main aspects in the chemo-preventive approach to patients at high risk for breast and ovarian cancer, focusing on different pharmacological risk reduction strategies, ongoing phase III chemoprevention studies in carriers of BRCA1/2 germline mutation, the psychological and clinical factors implicated in decision making about a trial, and the possible impact of the trial design on the overall acceptability and adherence.

KW - BRCA mutations

KW - Chemoprevention

KW - Clinical trials

KW - Ethics

KW - Patient adherence

UR - http://www.scopus.com/inward/record.url?scp=84886283213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886283213&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdt328

DO - 10.1093/annonc/mdt328

M3 - Article

C2 - 24131969

AN - SCOPUS:84886283213

VL - 24

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL.B

M1 - mdt328

ER -